Sani G
Department of Neuroscience, of Psychiatry, Università Cattolica del Sacro Cuore
ArticleKetamine
The association between anhedonia and quality of life in treatment-resistant depression: effects of a three-month treatment with esketamine nasal spray
ArticleKetamine
Improvements in Functioning with Esketamine Nasal Spray versus Quetiapine Extended Release in Patients with Treatment Resistant Depression
ArticleKetamine
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience).
ArticleKetamine
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.
ArticleKetamine
Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report.
ArticleKetamine
New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality.
ArticleMDMA
MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence.
ArticleKetamine
The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression.
ArticleKetamine
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
ArticleKetamine